Moderna, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +35

Moderna Stock Has Doubled in 2026, But Wall Street Still Isn’t Convinced

📈 Moderna stock has risen over 170% year-to-date in 2026, reaching highs near $77 according to Piper Sandler.

💰 Q1 2026 revenue reached $389 million, up 260% year-over-year, with international markets contributing 80% of top-line sales.

📉 GAAP net loss for the quarter was $1.3 billion, heavily impacted by a $178 million Arbutus settlement and $1.3 billion in contingent legal costs.

⚖️ The company faces ongoing litigation including a new CureVac lawsuit with potential costs up to $1.3 billion.

🔬 Oncology pipeline shows promise with Phase 2b melanoma data read as relatively well at ASCO in June.

📅 FDA PDUFA date for the mRNA-1010 flu vaccine is set for August 5, 2026, providing a tangible near-term catalyst.

📊 Analyst consensus ratings remain largely 'Hold' with price targets ranging widely from $18 to $77.

🏦 Susquehanna Financial Group aggressively cut its Moderna stake by 96.6% in Q1 2026, dumping roughly 1.56 million shares.

💼 Moderna President Stephen Hoge sold $3.6 million in shares on July 15 via a pre-planned 10b5-1 transaction.

🚀 Long-term revenue from assets like the lupus CAR-T program will not begin until at least 2028.

⚠️ Analysts characterize Moderna as a high-risk, catalyst-driven company rather than a core long-term compounder.

Bullish Signals
  • Moderna stock has doubled in 2026 with a year-to-date rise of over 170% by early July.
  • Q1 2026 revenue surged to $389 million, representing a 260% increase from the prior year.
  • Net product sales increased by 309% to $352 million in Q1 2026.
  • The company achieved a 26% year-over-year reduction in adjusted cash costs, demonstrating improved operational discipline.
  • International markets now account for approximately 80% of total revenue, indicating a successful geographic diversification.
  • Phase 2b adjuvant melanoma follow-up results reported at ASCO were read as relatively well.
  • Piper Sandler raised its price target to $77 from $69, citing the company's Science Day event and data updates.
  • The FDA has renewed its review of the mRNA-1010 flu vaccine with a PDUFA date of August 5, 2026.
Risk Factors
  • GAAP net loss for Q1 2026 was $1.3 billion, significantly inflated by non-operating items.
  • The company incurred a $178 million charge related to the Arbutus patent settlement.
  • Moderna faces up to $1.3 billion in contingent legal costs associated with ongoing litigation, including the CureVac lawsuit.
  • Susquehanna Financial Group reduced its Moderna holding by 96.6% in Q1 2026, selling approximately 1.56 million shares.
  • Moderna President Stephen Hoge executed a pre-planned stock sale of $3.6 million on July 15 at a price far above recent trading levels.
  • Analyst consensus ratings remain largely 'Hold' with a wide spread in price targets ranging from $18 to $77.
Full Analysis
Moderna Inc. (NASDAQ: MRNA) has seen its stock price double in 2026, rising over 170% year-to-date by early July and remaining up 90-100% by mid-July. This surge is driven by modest but significant financial improvements, including Q1 2026 revenue of $389 million, a 260% year-over-year increase, and a 26% reduction in adjusted cash costs. International markets now account for approximately 80% of top-line revenue, signaling a successful shift away from domestic post-pandemic demand. Despite the stock rally, Wall Street sentiment remains mixed with consensus ratings largely at 'Hold' and analyst price targets ranging widely from $18 to $77. The company reported a GAAP net loss of $1.3 billion for Q1 2026, inflated by a $178 million Arbutus patent settlement and up to $1.3 billion in contingent legal costs related to ongoing litigation, including a new CureVac lawsuit. Institutional behavior reflects this caution, with Susquehanna cutting its stake by 96.6% and Moderna President Stephen Hoge executing a pre-planned stock sale. The bull case relies on the oncology pipeline, which includes Phase 2b melanoma data showing relative strength and upcoming Phase 3 interim results later in 2026. A key near-term catalyst is the FDA's renewed review of the mRNA-1010 flu vaccine with a PDUFA date of August 5. However, long-term revenue from assets like a lupus CAR-T program will not materialize until at least 2028, leaving Moderna in a critical crossroads between pipeline validation and significant cash burn. Analysts view Moderna as a high-risk, catalyst-driven company rather than a core compounder, with the wide spread in price targets reflecting uncertainty about future commercialization. While some hedge funds have increased their holdings, the substantial institutional selling and pending litigation costs suggest that the stock's dramatic re-rating is based more on incremental updates than definitive evidence of long-term value creation.